306 related articles for article (PubMed ID: 17803521)
1. Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease.
Sharma R; McMillan CR; Niles LP
J Pineal Res; 2007 Oct; 43(3):245-54. PubMed ID: 17803521
[TBL] [Abstract][Full Text] [Related]
2. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.
Liu WG; Lu GQ; Li B; Chen SD
Parkinsonism Relat Disord; 2007 Mar; 13(2):77-88. PubMed ID: 16963309
[TBL] [Abstract][Full Text] [Related]
3. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
Sharma R; McMillan CR; Tenn CC; Niles LP
Brain Res; 2006 Jan; 1068(1):230-6. PubMed ID: 16375867
[TBL] [Abstract][Full Text] [Related]
4. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
[TBL] [Abstract][Full Text] [Related]
5. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
Bouchez G; Sensebé L; Vourc'h P; Garreau L; Bodard S; Rico A; Guilloteau D; Charbord P; Besnard JC; Chalon S
Neurochem Int; 2008 Jun; 52(7):1332-42. PubMed ID: 18372079
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson's disease rat model.
Gu S; Huang H; Bi J; Yao Y; Wen T
Brain Res; 2009 Feb; 1257():1-9. PubMed ID: 19111525
[TBL] [Abstract][Full Text] [Related]
7. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
Andereggen L; Meyer M; Guzman R; Ducray AD; Widmer HR
Brain Res; 2009 Jun; 1276():39-49. PubMed ID: 19389387
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Parkinson disease with C17.2 neural stem cells overexpressing NURR1 with a recombined republic-deficit adenovirus containing the NURR1 gene.
Li QJ; Tang YM; Liu J; Zhou DY; Li XP; Xiao SH; Jian DX; Xing YG
Synapse; 2007 Dec; 61(12):971-7. PubMed ID: 17879263
[TBL] [Abstract][Full Text] [Related]
9. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
10. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
11. Functional effect of FGF2- and FGF8-expanded ventral mesencephalic precursor cells in a rat model of Parkinson's disease.
Jensen P; Pedersen EG; Zimmer J; Widmer HR; Meyer M
Brain Res; 2008 Jul; 1218():13-20. PubMed ID: 18513704
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat.
Blandini F; Cova L; Armentero MT; Zennaro E; Levandis G; Bossolasco P; Calzarossa C; Mellone M; Giuseppe B; Deliliers GL; Polli E; Nappi G; Silani V
Cell Transplant; 2010; 19(2):203-17. PubMed ID: 19906332
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive use of the non-ionic surfactant Poloxamer 188 improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson's disease.
Quinn M; Mukhida K; Sadi D; Hong M; Mendez I
Eur J Neurosci; 2008 Jan; 27(1):43-52. PubMed ID: 18093176
[TBL] [Abstract][Full Text] [Related]
14. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers.
Niles LP; Armstrong KJ; Rincón Castro LM; Dao CV; Sharma R; McMillan CR; Doering LC; Kirkham DL
BMC Neurosci; 2004 Oct; 5():41. PubMed ID: 15511288
[TBL] [Abstract][Full Text] [Related]
15. Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease.
Harvey BK; Mark A; Chou J; Chen GJ; Hoffer BJ; Wang Y
Brain Res; 2004 Oct; 1022(1-2):88-95. PubMed ID: 15353217
[TBL] [Abstract][Full Text] [Related]
16. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
Ye M; Wang XJ; Zhang YH; Lu GQ; Liang L; Xu JY; Chen SD
Brain Res; 2007 Apr; 1142():206-16. PubMed ID: 17336273
[TBL] [Abstract][Full Text] [Related]
17. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
18. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Kobayashi K; Takeuchi A; Yano A; Muraoka K; Matsui T; Miyoshi Y; Hamada H; Date I
Eur J Neurosci; 2004 Mar; 19(6):1494-504. PubMed ID: 15066146
[TBL] [Abstract][Full Text] [Related]
20. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
